The Cancer Letter

Inside information on cancer research and drug development

Clinical Roundup

Adjuvant Keytruda provides higher QoL than standard of care immunotherapy in melanoma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Patients with high-risk stage III-IV melanoma who received Keytruda (pembrolizumab) after surgery reported a better quality of life than patients who received the previous standard-of-care treatment with either ipilimumab or high-dose interferon, according to a large clinical trial led by the SWOG Cancer Research Network.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account